ESMO 2025 preview – Roche comes clean on TIGIT
Four more failed tiragolumab trials, including Imbrave-152, will feature.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Alentis doubles down on Claudin1
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
Joyo starts its first pivotal trial
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
Roche sets up a breast cancer déjà vu
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
